- Home
- YMAT vs ADVM Comparison
YMAT vs ADVM Comparison
Compare YMAT & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAT
- ADVM
- Stock Information
- Founded
- YMAT 1970
- ADVM 2006
- Country
- YMAT Taiwan
- ADVM United States
- Employees
- YMAT N/A
- ADVM N/A
- Industry
- YMAT Recreational Games/Products/Toys
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YMAT Consumer Discretionary
- ADVM Health Care
- Exchange
- YMAT Nasdaq
- ADVM Nasdaq
- Market Cap
- YMAT 76.4M
- ADVM 66.3M
- IPO Year
- YMAT 2025
- ADVM 2014
- Fundamental
- Price
- YMAT $1.42
- ADVM $3.02
- Analyst Decision
- YMAT
- ADVM Strong Buy
- Analyst Count
- YMAT 0
- ADVM 4
- Target Price
- YMAT N/A
- ADVM $19.75
- AVG Volume (30 Days)
- YMAT 735.7K
- ADVM 84.1K
- Earning Date
- YMAT 01-01-0001
- ADVM 11-03-2025
- Dividend Yield
- YMAT N/A
- ADVM N/A
- EPS Growth
- YMAT N/A
- ADVM N/A
- EPS
- YMAT 0.07
- ADVM N/A
- Revenue
- YMAT $17,563,985.00
- ADVM $1,000,000.00
- Revenue This Year
- YMAT N/A
- ADVM $1,836.70
- Revenue Next Year
- YMAT N/A
- ADVM N/A
- P/E Ratio
- YMAT $20.27
- ADVM N/A
- Revenue Growth
- YMAT N/A
- ADVM N/A
- 52 Week Low
- YMAT $1.15
- ADVM $1.78
- 52 Week High
- YMAT $6.45
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- YMAT N/A
- ADVM 50.02
- Support Level
- YMAT N/A
- ADVM $2.93
- Resistance Level
- YMAT N/A
- ADVM $3.59
- Average True Range (ATR)
- YMAT 0.00
- ADVM 0.22
- MACD
- YMAT 0.00
- ADVM -0.02
- Stochastic Oscillator
- YMAT 0.00
- ADVM 13.64
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.